喹硫平与氯丙嗪治疗精神分裂症临床分析  

A controlled study between quetiapine and chlorpromazine in the treatment of schizophrenia

作　　者：黄河[1] 郭玉花[1] 陈晓燕[1] 

机构地区：[1]福建省南平市宁康医院,福建南平353000

出　　处：《中国民康医学》2012年第21期2597-2598,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:探讨喹硫平治疗精神分裂症的临床疗效。方法:61例精神分裂症患者随机分成两组,分别予以喹硫平和氯丙嗪治疗,疗程8周。以阳性和阴性症状量表(PANSS)[1]评定疗效及治疗中出现的症状量表(TESS)[1]评定不良反应。结果:两组疗效无显著性差异(P>0.05),喹硫平组不良反应明显少于氯丙嗪组,依从性更高。结论:喹硫平与氯丙嗪对精神分裂症患者都有较好疗效,但奎硫平对减轻患者不良反应明显优于氯丙嗪。Objective：To study the influence of quetiapine on chnical efficacy. Methods：Sixty -one patients with schizophre- nia were diveded into two groups randomly. They were treated with quetiapine and chlorpromazine respectively for 8 weeks. The effica- cy were evaluated with positive and negative syndrome scale （PANSS） and adverse effects were evaluated with treament emergent symptoms scale （TESS）. Results： There was no significant difference in clinical efficacy between the two groups. Patients in quetiap- ine group less than chlorpromazine group adverse effects. The compliance of quetiapine was significantly better than that of chlorproma- zinc. Conclusions： Quetiapine have similar clinical efficacy as chlorpromazine in the treatment of schizophrenia, with more improve- ment to reduce side effects.

关 键 词：喹硫平 氯丙嗪 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]